HCA Healthcare, Inc. (HCA)

HCA presents a contradictory setup that does not support the STRONG_BUY pre-screen. While fundamentals are solid (low P/E of 12.33, strong EPS growth of 29.2%, Bernstein bullish call with 38.4% upside), the technicals are deeply negative: price has fallen 15.5% from $433 peak (May 1) to $389.11 (today), RSI at 42 shows weakness but not yet capitulation, MACD is still in negative territory with only marginal convergence, and the stock is trading 16% below the 200-day SMA. The pre-screen score of 1.38/10 is itself weak, and recent volume surges (2.7M on May 19; 2.4M on May 29; 2.4M on Jun 1) coincided with heavy selling pressure, not accumulation. Macro backdrop is mixed—stable rates support healthcare, but Fear & Greed at 33 and recent sector rotation toward energy/finance create headwinds. News is constructive (education expansion, India growth play, analyst upgrade), but the magnitude of the recent drawdown suggests these catalysts may not yet be fully priced in—or that other headwinds (margin concerns, execution risk on M&A) are offsetting them. The risk of further downside to support near $360–$370 outweighs near-term momentum.